New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareThymagen vs PT-141 (Bremelanotide)

Thymagen vs PT-141 (Bremelanotide)

Side-by-side comparison of key properties, dosing, and research.

Immune Support
Thymagen
Sexual Health & Libido
PT-141 (Bremelanotide)
Summary
Thymagen is a dipeptide bioregulator (Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the thymus gland. It supports T-lymphocyte maturation, thymic function, and immune system normalization. As the thymus involutes with age (thymic atrophy), immune competence declines. Thymagen is used to support immune restoration, particularly in aging, post-illness recovery, and immunodeficiency states.
PT-141 (Bremelanotide) is a cyclic peptide melanocortin receptor agonist that enhances sexual desire and arousal through central nervous system mechanisms. It is FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD).
Half-Life
Short (minutes); sustained gene-regulatory effects
2–3 hours
Admin Route
SubQ, Oral
SubQ
Research
Typical Dose
10 mg per day
0.5–1.75 mg
Frequency
Daily for 10–30 days
As needed (not daily)
Key Benefits
  • Supports thymic epithelial cell function and T-cell maturation
  • May partially restore thymic output reduced by age-related atrophy
  • Normalizes T-lymphocyte subpopulation balance
  • Supports immune recovery after illness, surgery, or chemotherapy
  • Anti-aging effects on thymic tissue
  • Complementary to Thymosin Alpha-1 and Thymalin in immune protocols
  • May improve vaccine responsiveness in older individuals
  • Enhances sexual desire and libido in both men and women
  • Improves arousal through central nervous system activation
  • Effective for psychological erectile dysfunction
  • Works for female sexual arousal disorder
  • May improve sexual satisfaction and intensity
  • Fast-acting — effects within 45–60 minutes
  • FDA-approved for HSDD in premenopausal women
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant immunological adverse events reported
  • Nausea (most common — 40% of users in clinical trials)
  • Facial flushing and warmth
  • Transient blood pressure changes (typically increase then normalize)
  • Headache
  • +2 more
Stacks With